MIGRAINE BURDEN OF ILLNESS AMONG A COMMERCIALLY INSURED US POPULATION (IFORM-I)
Author(s)
Bridget L. Balkaran, MPH, DrPH1, Dannielle Lebovitch, MPH1, Cynthia Gutierrez, M.D., MBA1, Earl Burrell, PhD1, Zhengfan Wang, PhD1, Syvart Dennen, PhD1, Jonathan Bouchard, MS, RPh2;
1Genesis Research Group, Hoboken, NJ, USA, 2Ipsen Biopharmaceuticals, Cambridge, MA, USA
1Genesis Research Group, Hoboken, NJ, USA, 2Ipsen Biopharmaceuticals, Cambridge, MA, USA
OBJECTIVES: Migraine is a major cause of disability and considerable economic burden in the United States owing to its high prevalence and significant impact on quality of life. We examined treatment patterns, and healthcare resource utilization (HCRU) and costs among patients with migraine relative to a migraine-free population.
METHODS: This noninterventional, retrospective analysis of MarketScan data identified patients aged ≥18 years with medical encounters in the US between June 30, 2022 and June 30, 2023. The migraine cohort included patients with ≥1 confirmed ICD-10 diagnosis code for migraine during the identification period (index date) and pre-index, as well as 6 months of continuous enrollment before index (baseline) through 12 months post-index (follow-up). Patients with evidence of malignancy during the study period were excluded. Patient demographics, clinical characteristics, HCRU, costs, and treatment patterns were compared with patients with medical claims during the same period without migraine, matched 1:1 using direct matching.
RESULTS: The migraine and matched non-migraine cohorts included 72,642 patients each. Age and sex were well balanced between groups; mean (SD) age at index was 45-46 (13-14) and ~86% of patients were female. Patients with migraine had higher rates of comorbidities compared with patients without migraine, including anxiety (33% vs 12%), circulatory disorders (32% vs 17%), and depression (23% vs 8%). The most common pharmacotherapies in the migraine cohort during follow-up were prescription nonsteroidal anti-inflammatory drugs (46%), triptans (41%), and opioids/opioid combinations (36%). Median (IQR) total healthcare cost was $12,516 ($21,094) and $2,946 ($6,814) per patient in the migraine cohort and the matched non-migraine cohort, respectively.
CONCLUSIONS: Patients with migraine experience substantially greater comorbidity burden and healthcare resource utilization and costs compared with matched non-migraine individuals. Findings from this study highlight the need for optimized care for patients with migraine to reduce their clinical and economic burden.
METHODS: This noninterventional, retrospective analysis of MarketScan data identified patients aged ≥18 years with medical encounters in the US between June 30, 2022 and June 30, 2023. The migraine cohort included patients with ≥1 confirmed ICD-10 diagnosis code for migraine during the identification period (index date) and pre-index, as well as 6 months of continuous enrollment before index (baseline) through 12 months post-index (follow-up). Patients with evidence of malignancy during the study period were excluded. Patient demographics, clinical characteristics, HCRU, costs, and treatment patterns were compared with patients with medical claims during the same period without migraine, matched 1:1 using direct matching.
RESULTS: The migraine and matched non-migraine cohorts included 72,642 patients each. Age and sex were well balanced between groups; mean (SD) age at index was 45-46 (13-14) and ~86% of patients were female. Patients with migraine had higher rates of comorbidities compared with patients without migraine, including anxiety (33% vs 12%), circulatory disorders (32% vs 17%), and depression (23% vs 8%). The most common pharmacotherapies in the migraine cohort during follow-up were prescription nonsteroidal anti-inflammatory drugs (46%), triptans (41%), and opioids/opioid combinations (36%). Median (IQR) total healthcare cost was $12,516 ($21,094) and $2,946 ($6,814) per patient in the migraine cohort and the matched non-migraine cohort, respectively.
CONCLUSIONS: Patients with migraine experience substantially greater comorbidity burden and healthcare resource utilization and costs compared with matched non-migraine individuals. Findings from this study highlight the need for optimized care for patients with migraine to reduce their clinical and economic burden.
Conference/Value in Health Info
2026-05, ISPOR 2026, Philadelphia, PA, USA
Value in Health, Volume 29, Issue S6
Code
EE455
Topic
Economic Evaluation
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
No Additional Disease & Conditions/Specialized Treatment Areas, SDC: Neurological Disorders